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Aims: To assess the effects of peroxisome proliferator-activated receptor (PPAR) agonists on glucose tolerance
and hepatic lipid metabolism in diet-induced obese mice.
Main methods: Male C57BL/6 mice received a standard chow diet (SC, 10% energy as lipids) or high-fat diet
(HF, 50% energy as lipids) for 10 weeks, after which treatment was initiated, forming the groups: SC group, HF
group, HF-BZ group (HF+ bezaﬁbrate, pan-PPAR agonist), HF-WY group (HF+WY-14643, PPARalpha agonist)
and HF-GW group (HF + GW1929, PPARgamma agonist). Treatments lasted for four weeks. Insulin resistance
and liver remodeling were evaluated by biochemical and molecular approaches.
Key ﬁndings: The HF and HF-GWmice were overweight. Conversely, the HF-BZ and HF-WYmice presented with
body masses equal to those of the SC mice. All treatments restored insulin sensitivity and blood lipid and
adiponectin levels. Hepatic steatosis was prevented in the HF-WY and HF-BZ mice as shown by the elevated
mRNA levels of PPARalpha and Carnitine palmitoyl transferase-1a in both groups, which favored enhanced
beta-oxidation. Marked decreases in liver triacylglycerol levels conﬁrmed these ﬁndings. In contrast, the HF-
GW mice exhibited increased PPARgamma and fatty acid translocase/CD136 mRNA levels, contributing to
enhanced hepatic lipogenesis.
Signiﬁcance: The WY14643 and bezaﬁbrate treatments most effectively improved the adverse metabolic and
hepatic effects caused by obesity and IR. The results reinforce the central role of PPARalpha, aswell as its contrary
relationship to PPARgamma in the regulation of metabolic homeostasis and lipolytic pathways in the liver.© 2015 Elsevier Inc. All rights reserved.Introduction
Nonalcoholic fatty liver disease (NAFLD) includes multiple condi-
tions due to fat deposition within hepatocytes. The hepatic steatosis
rate reveals the imbalance between input (lipolysis in white adipose
tissue, de novo lipogenesis and lipogenesis), and output (lipoprotein
synthesis and secretion) of free fatty acids in hepatic tissue [1].
Peroxisome proliferator-activated receptors (PPARs) are associated
with nutrient metabolism and cellular proliferation [2]. PPARalpha
activation is linked to ameliorated lipoprotein proﬁle, and directly stim-
ulates hepatic beta-oxidation by inducing the transcription of several
genes that participate in this process [3]. PPARbeta/delta activation inetria, Metabolismo e Doenca
ado do Rio de Janeiro, Av 28 de
.: +55 21 2868 8316; fax: +55
bosa-da-Silva),
gmail.com (D.C. Magliano),
ail.com (M.B. Aguila),
arim-de-Lacerda).hepatic tissue participates in Kupffer cell regulation, acting as an anti-
inﬂammatorymolecule by decreasing the expression of genes encoding
proteins involved in inﬂammatory pathways [4]. PPARgamma is some-
what expressed in hepatic tissue and is related to glucose and lipid
metabolism along with PPARalpha and PPARbeta/delta [5].
The rise in obesity rates worldwide encourages a proposition of new
approaches to reinforce the existing treatments [6]. Therefore, the
work aims to investigate and compare the effects of treatment with
WY14643, which is a selective PPARalpha agonist, GW1929, which is a
selective PPARgamma agonist and bezaﬁbrate, which is a pan-PPAR
agonist, on glucose tolerance and hepatic lipid metabolism at the gene
level in diet-induced obese mice.
Materials and methods
Animals and diet
The Animal Ethics Committee of the State University of Rio de
Janeiro approved the present protocol (Number CEUA/012/2011), and
the processes were run out according to the guidelines for animal
experimentation (NIH Publications No. 85-23, revised in 1996).
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peratures (21 ± 1 °C), humidity (60 ± 10%) and a 12 h light/dark cycle
(1:00 AM to 1:00 PM light) with food and water ad libitum. Mice re-
ceived standard chow (SC, 10% of energy as lipids, 15 kJ/g of diet, n =
10) or HFty diet (HF, 50% of energy as lipids, 21 kJ/g of diet, n = 40).
Diets are shown in detail in Table 1. After ten weeks, the animals fed
the high-fat (HF) diet were then randomly assigned to one of the
following groups (treatment lasted four weeks and the drugs were
combined into the diets as follows):
a) Standard chow (SC group; 10% energy from fat, n = 10);
b) High-fat diet (HF group; 50% energy from fat, n = 10);
c) High-fat diet + bezaﬁbrate (HF-BZ group; pan-PPAR agonist,
100 mg/kg, n = 10);
d) High-fat diet + WY14643 (HF-WY group; PPARalpha agonist,
3 mg/kg, n = 10);
e) High-fat diet + GW1929 (HF-GW group; PPARgamma agonist,
5 mg/kg, n = 10).
The diets followed the American Institute of Nutrition recommenda-
tions (AIN-93M) [7] and were manufactured by PragSolucoes (Jau, SP,
Brazil). Bodymass (BM)was evaluated once aweek, and food consump-
tionwasmeasured for 72h prior to sacriﬁce using the Compulse v 2.7.13
software (Harvard/Panlab, Barcelona, Spain). Energy intake was calcu-
lated by multiplying the amount of food consumption by the energy
content of the diet.
Blood glucose test analysis
Oral glucose tolerance tests (OGTTs) were taken at 13 weeks after
induction of the dietary treatments. OGTTs were performed using a glu-
cose overload of 1.0 g/kg, given after a six-hour fasting period through
orogastric gavage. Blood glucose concentrations were measured before
glucose administration (0 min) and at 15, 30, 60 and 120 min after
administration. Blood samples taken from the tail vein were analyzed.
Euthanasia
After 14weeks of testing, themicewere deeply anesthetized (i.p. so-
dium pentobarbital, 150 mg/kg) and killed by exsanguination. The
serumwas obtained via centrifugation (120 g for 15min) at room tem-
perature and kept at−20°°C until analysis. The liver was immediately
removed, weighed, ﬁxed and prepared as described [8]. Additional
parts of the liver were quickly frozen for molecular evaluations. The
left tibia was dissected and measured to correct for liver mass [9].Table 1
Detailed diet composition.
Ingredients (g/Kg)
SC HF
Casein (≥85% of protein) 140.0 175.0
Cornstarch 620.69 620.69
Sucrose 100.0 100.0
Soybean oil 40.0 40.0
Lard – 238.0
Cholesterol (mg) – 226,1
Fiber 50.0 50.0
Vitamin mix 10.0 10.0
Mineral mix 35.0 35.0
L-Cystine 1.8 1.8
Choline 2.5 2.5
Antioxidant 0.008 0.008
Total mass 1000.0 1000.0
Proteins (% energy) 14 14
Carbohydrates (% energy) 76 36
Lipids (% energy) 10 50
Energy content (kcal/Kg) 3811 5000Plasma analysis
Total cholesterol (TC), triacylglycerols (TG), alanine aminotransfer-
ase (ALT) and gamma-glutamyl transferase (gGT) were measured
using kinetic-colorimetric methods based on the manufacturer's in-
structions (Bioclin System II, Quibasa, Belo Horizonte, MG, Brazil). The
serum concentrations of insulin, leptin andproinﬂammatory adipokines
(plasminogen activator inhibitor-1 (PAI-1), and resistin) were mea-
sured using Multiplex Biomarker Immunoassays with Luminex xMAP
technology (Millipore, Billerica, MA, USA, Cat. No. MMHMAG-44K-08),
whereas serum concentrations of adiponectin were evaluated with
MADPK-71K-01. A Luminex 200 analyzer with the Xponent/Analyst
software version 4.2 was used for result interpretation.Liver
Liver TG was measured as described [10]. Brieﬂy, frozen liver sam-
ples (around 50 mg) plus 1 ml of isopropanol were placed in an ultra-
sonic processor and homogenate was centrifuged at 2000 g, and 5 ml
of the supernatant was analyzed with an automatic analyzer (K55,
Bioclin System II; Quibasa) using a kit for measuring TG.
Formalin-ﬁxed liver specimens were embedded in Paraplast Plus
(Sigma-Aldrich, St. Louis, MO, USA), and 5-μm-thick sections were
stained with hematoxylin and eosin and Sirius Red. The digital im-
ages were acquired blindly and randomly (Leica DMRBE microscope,
Wetzlar, Germany, and Lumenera Inﬁnity 1-5c camera, Ottawa,
Canada). The stereological estimation of liver steatosis was made
by point-counting as mentioned previously [10,11].Immunoﬂuorescence
The liver sections (5 μm thick) were deparafﬁnized, and antigen re-
trieval was performed using citrate buffer, pH 6.0. Then, sections were
blocked with glycine at 2% and incubated with anti-smooth muscle
alpha actin antibody diluted in PBS/BSA 1% for 2 h. Afterward, samples
were incubated with a secondary antibody conjugated with Alexa.
DAPI was used to stain the nuclei. Coverslips were mounted with
slow-fade (Invitrogen, Waltham, Massachusetts, USA) to keep ﬂuores-
cence. Negative controls were obtained after the omission of the prima-
ry antibody. The confocal laser microscope C2 (Nikon Inc., Tokyo) was
used to evaluate the results.RT-qPCR
RT-qPCR was executed as described elsewhere [12]. The qPCR
primers were designed using the Primer3 online software, and endoge-
nous control TATA-binding protein (TBP) was used to normalize the ex-
pression levels of the selected genes. The following primers were used:
CPT-1 (FW AAGGAATGCAGGTCCACATC; RV CCAGGCTACAGTGGGACA
TT), (fatty acid translocase)/CD36 (FW TGCATTTGCCAATGTCTAGC; RV
CCCTCCAGAATCCAGACAAC), PPARalpha (FW TCGAGGAAGGCACTAC
ACCT; RV TCTTCCCAAAGCTCCTTCAA), PPARgamma2 (FW ACGATC
TGCCTGAGGTCTGT; RV CATCGAGGACATCCAAGACA), SREBP-1c
(FW TCTGCCTTGATGAAGTGTGG; RV AGCAGCCCCTAGAACAAACA),
PPARbeta/delta (FW GGTTGACCTGCAGATGGAAT; RV TGGAGCTCGA
TGACAGTGAC), FAS (FW TCGAGGAAGGCACTACACCT; RV CACCCACT
GGAAGCTGGTAT) and TBP (FW CAGCCTTCCACCTTATGCTC; RV TTGC
TGCTGCTGTCTTTGTT).
Negative controls were held after the blockade of cDNA in the
racks. RQ (relative expression ratio) of mRNA was calculated by
2−ΔΔCt equation, where −ΔCT expresses the difference between
the number of cycles (CT) of the target gene and the endogenous con-
trol. The expression of TBP was quantiﬁed for all samples via RT-qPCR
and used for normalization.
Table 2
Energy intake, liver mass, and blood and liver biochemistry data in mice of the groups studied. The groups are: standard chow, SC; high-fat diet, HF; bezaﬁbrate, pan-PPAR agonist BZ;
GW1929, PPARgamma agonist GW and WY14643, PPARalpha agonist WY. Values are mean ± SD. For superscripted values, P b 0.05 when: [a] compared to SC group, [b] compared to
HF group, [c] compared to HF-BZ group and [d] compared to HF-WY group (one-way ANOVA and Holm–Sidak post-hoc test).
Data Groups
SC (n = 10) HF (n = 10) HF-BZ (n = 10) HF-WY (n = 10) HF-GW (n = 10)
Energy intake (kJ) 43.05 ± 7.23 65.14 ± 9.02[a] 64.62 ± 10.85[a] 67.21 ± 7.68[a] 76.62 ± 17.87[a]
Liver mass (g) 1.09 ± 0.06 1.41 ± 0.21[a] 2.40 ± 0.11[b] 1.62 ± 0.28[c] 1.40 ± 0.04[c]
Total cholesterol (mg/dL) 113.80 ± 6.41 158.70 ± 8.62[a] 165.50 ± 26.64[a] 167.50 ± 12.54[a] 160.00 ± 12.31[a]
Plasma triacylglycerol (mg/dL) 34.80 ± 12.13 69.50 ± 6.15[a] 55.40 ± 4.26[a,b] 54.8 ± 3.04[a,b] 65.52 ± 4.86[a,b]
Liver triacylglycerol (mg/dL) 1.63 ± 0.36 2.89 ± 0.15[a] 2.11 ± 0.24[b] 1.77 ± 0.17[b] 2.77 ± 0.32[a,c,d]
Alanine aminotransferase (IU/L) 8.40 ± 0.90 11.2 ± 0.84[a] 9.3 ± 0.84[b] 9.2 ± 0.84[b] 8.0 ± 1.00[b]
γ-Glutamyl transferase (IU/L) 8.6 ± 0.5 10.5 ± 1.1[a] 8.4 ± 0.9[b] 7.2 ± 0.8[b] 8.2 ± 0.8[b]
Leptin (pg/ml) 64.5 ± 12.28 7851.5 ± 445.00[a] 986.4 ± 193.00[a,b] 100.5 ± 26.97[b] 2218 ± 237.00[a,b,c,d]
Adiponectin (pg/ml) 131.0 ± 17.84 78.0 ± 12.34[a] 141.0 ± 32.85[b] 129.0 ± 15.52[b] 283.0 ± 29.07[a,b,c,d]
Resistin (pg/ml) 867.6 ± 81.44 1351.7 ± 250.40[a] 755.6 ± 109.70[b] 421 ± 80.50[b,c] 1082.4 ± 204.80[b,c]
PAI-1 (pg/ml) 1264 ± 429.50 2767 ± 425.70[a] 2368 ± 440.30[a] 2880 ± 538.90[a] 2246 ± 292.30[a]
Insulin (UI/I) 21.46 ± 5.67 40.58 ± 6.11[a] 20.73 ± 6.41[b] 27.24 ± 2.55[b] 20.8 ± 4.95[b]
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Data are expressed as the mean ± standard deviation. All data
were examined for normality and homoscedasticity of variance, and
then a 1-way analysis of variation (ANOVA) was established, followed
by the Holm–Sidak post-hoc test. Statistical signiﬁcance was considered
when P-value ≤ 0.05 (GraphPad Prism v. 6.05 for Windows, GraphPad
Software, La Jolla, CA, USA).
Results
Body mass, energy intake and glucose tolerance (Table 2 and Fig. 1)
The supply of the HF diet for 10 weeks caused a progressive increase
in BM for the HF group signiﬁcantly higher than that in the SC group
(+30%; P b 0.0001), which could be explained easily by the higher en-
ergy intake of the HF group (+50%; P b 0.05). Drug treatment for four
weeks caused signiﬁcant BM reductions in the HF-BZ and HF-WY
groups in comparison with the HF group (−35% and−30%, respective-
ly; P b 0.0001), although the energy intake levels of these two
groups were similar to those of the untreated HF group. Conversely,
the HF-GW group did not show decreased BM after the treatment, and
when ﬁnalizing the experiment, the BM of this group was not signiﬁ-
cantly different from that of the HF group (P= 0.34).Fig. 1. Bodymass evolution of (A) all mice; oral glucose tolerance test curves (B). The groups are
agonist GWandWY14643, PPARalpha agonistWY. Data are presented as themean± SD, n=5
SCgroup; ††, ††† and †††† indicates P b 0.01, P b 0.001 and P b 0.0001, respectively, compared toH
HF-BZ group; ‡‡, ‡‡‡ and ‡‡‡‡ indicate P b 0.01, P b 0.001 and P b 0.0001, respectively, compareThe HF group was glucose intolerant as demonstrated by the in-
creased AUC for the OGTT (+40%; P b 0.0001). In contrast, alongwith re-
ductions in BMs, the HF-BZ, and HF-WY groups showed improved
glucose tolerance because these groups were faced with a lower OGTT
curve (−25%, P = 0.004) than that of the HF group. In addition, the
HF-GW group showed improved glucose tolerance (−40%, P b 0.0001).
The HF group showed hyperinsulinemia (+90%; P b 0.001), which was
not seen in the SC group, while all treated groups showed reduced plas-
ma insulin levels in contrast to the HF group (approximately−95% in
the HF-BZ and HF-GW and−50% in the HF-WY groups; P b 0.001).
Adipokines and lipid proﬁles (Table 2)
Both groups HF-BA andHF-WY had small BM and showed improved
levels of leptin, resistin and adiponectin, which were comparable to the
SC group. Moreover, the HF-GW group exhibited improved adipokine
levels compared to the HF group, but higher values than the SC group.
None of the three treatments normalized PAI-1 levels, which remained
comparable to those of the HF group.
Lipid proﬁles were assessed to conﬁrm the beneﬁcial effects of
GW1929 independent of BM. The HF group showed increased TC (1.4-
fold; P b 0.01) and TG (2-fold; P b 0.0001) than the SC group. In addition,
the treated groups presented reduced TG (P=0.02), but the treatments
did not affect TC levels.: standard chow, SD; HF diet, HF; bezaﬁbrate, pan-PPAR agonist BZ; GW1929, PPARgamma
for each group. *** and **** indicate P b 0.001 and P b 0.0001, respectively, compared to the
F group; $$$ and $$$$ indicate P b 0.01, P b 0.001 and P b 0.0001, respectively, compared to
d to HF-WY group.
Fig. 2. Photomicrographs of the liver (hematoxylin and eosin, same magniﬁcation). The groups are: standard chow, SD; HF diet, HF; bezaﬁbrate, pan-PPAR agonist BZ; GW1929,
PPARgamma agonist GW and WY14643, PPARalpha agonist WY. Liver appearance in the SC group (A), macro and microvesicular steatosis is commonplace in the untreated HF group
(B), larger hepatocytes are seen in HF-BZ group (C), liver appearance after peroxisome proliferator-activated receptor (PPAR)alpha activation in HF-WY (D), with the presence of
macro and microvesicular steatosis is seen in HF-GW (E) and the volume density of steatosis is illustrated for each group (F). Data are presented as the mean ± SD, n = 5 for each
group. **** indicates P b 0.0001 compared to SC group; †††† indicates P b 0.0001 compared to HF group; $$$$ indicates P b 0.0001 compared to HF-BZ group; ‡‡‡‡ indicates P b 0.0001
compared to HF-WY group.
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The liver mass of the HF group was heavier than the SC group
(+35%; P = 0.0006). Accordingly, the TG levels of the HF group were
80% higher (P b 0.0001) and the steatosis content was 150% higherFig. 3. Sirius Red staining in the liver, same magniﬁcation. The groups are: standard chow, SD
WY14643, PPARalpha agonist WY. Normal hepatic parenchyma was observed in the SC group
ﬁbrosis was observed in the HF-BZ group (C), HF-WY group (D) and HF-GW group (E).(P b 0.0001) than the SC group. Interestingly, the HF-BZ group had
increased liver mass (+25%; P = 0.0009), but TG levels and steatosis
diminished compared to the HF group (−30% and−50%, respectively;
P b 0.0001). To assess whether this increase in liver mass could cause
liver damage, we measured plasma ALT and gGT concentrations and; HF diet, HF; bezaﬁbrate, pan-PPAR agonist BZ; GW1929, PPARgamma agonist GW and
(A), expressive liver ﬁbrosis areas were depicted in the HF group (B), and less extensive
77S. Barbosa-da-Silva et al. / Life Sciences 127 (2015) 73–81observed that the HF group had augmented levels of both hepatic
enzymes (+30% and +20%; P b 0.001) than the SC group. The HF-BZ
group preserved values similar to the SC group.
The HF-WY group showed lower TG levels (−65%; P b 0.0001) and
lower steatosis (−135%; P b 0.0001) than the HF group, but no signiﬁ-
cant difference in liver mass between the HF and HF-WY groups. In
contrast, GW1929 failed to override the effects of the HF diet on the
liver, and no substantial differences were found between the HF and
HF-GW groups. Similar to HF-BZ, both the HF-WY and HF-GW groups
presented improved plasma ALT levels compared to the HF group
(−15%; P= 0.02 for the HF-WY group, and−30%; P= 0.0001 for the
HF-GW group). The HF-WY and HF-GW groups showed reduced levels
of plasma gGT compared to theHF group (−30% and−20%, respective-
ly, P b 0.01).
Inﬂammation and ﬁbrosis in the liver (Figs. 3 and 4)
Immunoﬂuorescence demonstrated positive reactions for smooth
muscle alpha actin in groups fed HF diet, implying the role that chronic
dietary intake of excessive saturated fatty acids has in hepatic inﬂam-
mation. Of note, the HF-BZ group presented amarked reaction, suggest-
ing a greater activation of hepatic stellate cells (HSCs) in these animals.
This observation complieswith the higher gene expression of PPARbeta,
induced by the treatmentwith bezaﬁbrate. Hepaticﬁbrosis demonstrat-
ed by Sirius Red staining suggests HSC activation once all HF fed groups
presented clusters of ﬁbrosis within hepatic tissue, conﬁrming that theFig. 4. Liver immunoﬂuorescence for smooth muscle alpha actin, same magniﬁcation. The g
PPARgamma agonist GW and WY14643, PPARalpha agonist WY. Negative immunoreaction wa
HF-BZ group (C), HF-WY group (D) and HF-GW group (E). Activated hepatic stellate cells are mdiet is a signiﬁcant factor in the progression of NAFLD. However, the
treated groups showed less expressive ﬁbrosis than the untreated HF
group.
PPARalpha, PPARbeta, PPARgamma and target gene equilibrium in liver
(Figs. 5, 6 and 7)
In order to determine the inﬂuence of disrupted equilibrium of key
transcription factors associated with the NAFLD/NASH spectrum, we
performed RT-qPCR to evaluate PPAR isoforms and some target gene
levels. As expected, the HF group presented increased mRNA levels of
PPARgamma (P = 0.03) and SREBP-1c (P b 0.01), which are lipogenic
transcription factors in the liver, and diminished mRNA levels of
PPARalpha (P b 0.05). The HF-WY group presented high PPARalpha
(P b 0.0001) and low PPARgamma (P b 0.01) and SREBP-1c (P b 0.01)
mRNA levels as expected. The HF-GW group was not different from
the HF group concerning PPARgamma and PPARalpha expressions, but
showed an increased expression of SREBP-1c (P b 0.03). The HF-BZ
group had high PPARalpha (P b 0.001) and low PPARgamma
(P b 0.01) mRNA levels, but SREBP-1c was similar to the HF group.
When the PPARalpha/PPARgamma ratio was performed, a higher hepat-
ic beta oxidation capacity was found on the HF-WY group (P= 0. 002)
and on the HF-BZ group (P=0. 004) in comparisonwith the untreat-
ed HF group. This ﬁnding correlates with the marked increase in
PPARalpha gene expression in these groups compared to the un-
treated HF group.roups are: standard chow, SD; HF diet, HF; bezaﬁbrate, pan-PPAR agonist BZ; GW1929,
s observed in the SC group (A), positive immunoreaction was found in the HF group (B),
arked (arrows).
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(FAT)/CD36 and fatty acid synthase (FAS) was performed to investigate
whether the decreased TG and steatosis levels were due to enhanced
beta-oxidation. The HF and HF-GW groups had decreased mRNA levels
of CPT-1a (P b 0.01), and increasedmRNA levels of FAT/CD36 (P b 0.01).
In contrast, the HF-WY group had increased CPT-1a mRNA levels
(P b 0.0001) and decreased FAT/CD36 mRNA levels (P b 0.01). More-
over, the HF-BZ group showed increases in both CPT-1a (P b 0.0001)
and FAT/CD36 (P b 0.01) gene expression. A higher beta oxidation
capacity was observed with the CPT-1a/SREBP-1c ratio. This ratio was
higher in both the HF-BZ group (P = 0. 001) and the HF-WY group
(P b 0.0001) than the untreated HF group.
A FAS gene expression followed PPARgamma gene expression, being
enhanced in theHF andHF-GWgroupswhen compared to the SC group
(P b 0.02). Curiously, pan-PPAR activation by bezaﬁbrate elicited en-
hanced FAS gene levels (P b 0.01). However, the higher PPAR-alpha
and CPT-1a gene expression guaranteed higher metabolization of
hepatic lipids, avoiding accumulation. In the agreement to this, the
HF-WY group presented the weakest FAS gene expression.
Finally, PPARbeta gene expression was diminished in the HF group
in comparison to SC group (P = 0. 003). Only treatment with
bezaﬁbrate was able to induce PPARbeta gene expression signiﬁcantly
compared to HF group (P b 0.0001). When the PPAR balance was ana-
lyzed, considering the three PPAR isoforms, bezaﬁbrate induced all
PPAR isoform gene expression, but predominantly the alpha and
beta isoforms. As expected, HF-WY presented a greater activation of
PPARalpha as well as HF-GW induced PPARgamma.
Discussion
The current study compared the effects of treatments with different
PPAR agonists (PPARalpha, PPARgamma, and pan-PPAR agonist) onFig. 5. Gene expression levels of peroxisome proliferator-activated receptor (PPAR)alpha (A), P
chow, SD; HF diet, HF; bezaﬁbrate, pan-PPAR agonist BZ; GW1929, PPARgamma agonist GW an
expression levels of the selected genes. Data are presented as the mean ± SD, n = 5 for each
compared to SC group; ††, ††† and †††† indicate P b 0.01, P b 0.001 and P b 0.0001, respective
compared to HF-BZ group and ‡‡‡ indicates P b 0.001 compared to the HF-WY group.hepatic liver metabolism using a dietary murine model of obesity. The
three treatments led to improved glucose tolerance, plasma insulin,
and adipokine levels but disagreed with respect to their effects on
hepatic structure, inﬂammation, lipid metabolism and biochemistry.
Animal model and different dietary approaches are useful to mimic
the NAFLD observed in humans. However, the degree of hepatic
steatosis, inﬂammation and ﬁbrosis depend on the type of animal, the
nutritional manipulation and the duration of diet administration [13].
The HF diet is suitable to mimetize in the animal model the hepatic
alterations observed in humans. The HF diet is more appropriate than
methionine choline-deﬁcient diet, because it elicits insulin resistance
and proinﬂammatory adipokine proﬁle prior to lipid accumulation
within hepatocytes [13,14].
The HF diet induced pronounced weight gain during the observa-
tional period. It has been extensively demonstrated that being over-
weight and being obese are directly linked to IR, glucose intolerance
and increases in inﬂammatory adipokines [15], as observed in the HF
group. Treatment with WY14643 and bezaﬁbrate signiﬁcantly reduced
BM. This reduction has been shown to be an important contributor to
improved glucose tolerance and IR [16] and reduced inﬂammatory
adipokines [17], all of which were found in the HF-WY and HF-BZ
groups. Interestingly, GW1929 attenuated glucose intolerance, IR and
inﬂammation in a BM-independent manner as shown by the similar
BMs of theHF-GWand the untreatedHF group during the experimental
period. We have previously demonstrated that rosiglitazone, which is a
total PPARgamma agonist, can improve these parameters without alter-
ing BM [5]. Furthermore, PPARgamma agonists, such as pioglitazone
and rosiglitazone, have improved metabolic parameters in individuals
with NASH [18], but the clinical use of these agents has been limited
by off-target adverse effects, such as weight gain [19].
The high energy diets contribute signiﬁcantly to the development of
NAFLD/NASH in human and animal models. Concomitant with thePARbeta (B), PPARgamma (C) and PPAR balance (D) in the liver. The groups are: standard
dWY14643, PPARalpha agonist WY. TBP was used as an internal control to normalize the
group. *, **, *** and **** indicate P b 0.05, P b 0.01, P b 0.001 and P b 0.0001, respectively,
ly, compared to HF group; $$$ and $$$$ indicate P b 0.001 and P b 0.0001, respectively,
Fig. 6. Gene expression levels of carnitine palmitoyl transferase (CPT1a) (A), sterol regulatory element-binding protein (SREBP)1-c (B), fatty acid translocase (FAT)/CD36 (C) and fatty
acid synthase (D) in the liver. The groups are: standard chow, SD; HF diet, HF; bezaﬁbrate, pan-PPAR agonist BZ; GW1929, PPARgamma agonist GW and WY14643, PPARalpha agonist
WY. TATA binding protein (TBP) was used as an internal control to normalize the expression levels of the selected genes. Data are presented as the mean ± SD, n = 5 for each group.
*, **, *** and **** indicate P b 0.05, P b 0.01, P b 0.001 and P b 0.0001, respectively, compared to SC group; †† and †††† indicate P b 0.01 and P b 0.0001, respectively, compared to the
HF group; $$ and $$$$ indicate P b 0.01 and P b 0.0001, respectively, compared to the HF-BZ group and ‡‡‡ and ‡‡‡‡ indicate P b 0.001 and P b 0.0001, respectively, compared to the
HF-WY group.
79S. Barbosa-da-Silva et al. / Life Sciences 127 (2015) 73–81development of IR, liver damage includes lipogenesis activation through
overexpression of PPARgamma and SREBP-1c [20,21]. The current study
conﬁrmed that theHF diet accentuated the livermass, steatosis percent-
age and TG levels in the liver and demonstrated that the treatments led
to different results. First, WY14643 markedly diminished steatosis,
and consequently, TG levels in the liver without causing signiﬁcantFig. 7. The groups are: standard chow, SD; HF diet, HF; bezaﬁbrate, pan-PPAR agonist BZ; G
PPARgamma mRNA ratio in the liver (A) and CPT1a/SREBP1c mRNA ratio in the liver (B). Dat
P b 0.001 and P b 0.0001, respectively, compared to the SC group; †† and †††† indicate P b 0.0
and P b 0.0001, respectively, compared to the HF-BZ group; ‡‡ and ‡‡‡‡ indicate P b 0.01 and Pdifferences in liver mass compared with the HF group. Bezaﬁbrate also
diminished steatosis and TG levels, but enhanced liver mass. Finally,
GW1929 did not alter these data compared to the HF group.
PPARalpha activation byﬁbrates in the liver can cause hepatic perox-
isome proliferation and hepatomegaly, but these effects are lost
in humans, even when the ﬁbrates preserve PPARalpha activation.W1929, PPARgamma agonist GW and WY14643, PPARalpha agonist WY. PPARalpha/
a are presented as the mean ± SD, n = 5 for each group. *, *** and **** indicate P b 0.05,
1 and P b 0.0001, respectively, compared to the HF group; $$ and $$$$ indicate P b 0.01
b 0.0001, respectively, compared to the HF-WY group.
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in both species [12]. Both the HF-BZ and HF-WY groups presented en-
hanced PPARalpha mRNA levels, but only the HF-BZ group showed in-
creased liver mass, conﬁrming that not only PPARalpha activation, but
also ﬁbrates, can cause this effect in mice. Although animals treated
with bezaﬁbrate showed increased liver mass, this was not associated
with high levels of ALT or gGT, which is indicative of the absence of
liver damage in this group [22].
PPAR activation in the liver is associated with increased beta-
oxidation or the increased activity of lipogenic pathways [12].
PPARalpha is the primary activator of beta-oxidation through its target
genes, such as CPT-1a [23]. In contrast, PPARgamma participates in
lipogenic activities in the liver through its target genes, FAT/CD36 and
SREBP-1c [5,24]. CPT-1a is the mitochondrial gateway for fatty acid
entry into themitochondrial matrix. As such, it is considered themaster
regulator of hepatic mitochondrial beta-oxidation [25]. Both the HF-BZ
and HF-WY groups presented elevated mRNA levels of CPT-1a, which
favors beta-oxidation. On the other hand, only the HF-BZ group showed
elevated mRNA levels of FAT/CD36, which is responsible for promoting
a long-chain fatty acid (LCFA) transport into mitochondria, augmenting
oxidative capacity as long as CPT-1 is also upregulated [24,26].
Although FAT/CD36 is not crucial for fatty acid uptake in the liver, it
enables the initialmetabolism of LCFAs, which involves a chain shorten-
ing to allow fatty acid entry into the mitochondria by CPT-1 activation
(for molecules with a maximum of 20 carbons) [24]. The HF-WY
group had the weakest FAT–CD36 gene expression. However, this fact
did not compromise the beta-oxidation capacity of the group, because
the HF diet was based on lard (predominantly composed of saturated
fatty acids with 16 and 18 carbons in length). These fatty acids do not
rely on FAT/CD36 to enter the mitochondria [24,27]. In contrast, the
GW1929 and untreated HF groups favor the lipogenic pathway, as
proven by the enhanced mRNA levels of PPARgamma and FAT/CD36
and the diminished mRNA levels of PPARalpha and CPT-1a. In addition,
FAT/CD36 is a common target for various lipogenic genes, such as LXR,
PXR and PPARgamma and its upregulation leads to hepatic steatosis [28].
PPARgamma and SREBP-1c are essential for triggering hepatic lipo-
genesis [29,30]. Using a metabolic programmingmodel, we have previ-
ously demonstrated that PPARgamma, but not SREBP-1c, plays a role in
lipogenic activity in liver [12]. We conﬁrmed these data in the current
study by showing that bezaﬁbrate treatment optimizes beta-oxidation
without altering SREBP-1c mRNA levels. The PPARalpha activation
(WY14643 treatment) was able to decrease the expression levels of
PPARgamma and SREBP-1c in the liver, and consequently the lipogenic
activity.
Despite being a benign condition, NAFLD can progress to harmful
diseases such as NASH and liver ﬁbrosis [31]. This progression relies
on chronic inﬂammation, which was identiﬁed in all HF fed groups
after Sirius Red staining. However, the three treatments attenuated
this parameter, being efﬁcient to avoid NAFLD progression. In the
presence of chronic liver injury, hepatic stellate cells (HSCs) receive
signals that cause their transdifferentiation into a ﬁbroblast-like cell
that produce a temporary scar to protect the liver from further
injuries [32].
Activated HSCs cause hepatic ﬁbrosis if the triggering stimulus of
their activation is prolonged [33]. PPAR activation may interfere with
the quality and amount of extracellular matrix synthesis due to HSC
activation. Thus, PPARgamma activation may maintain HSCs quiescent
phenotype [34]. In fact, the HF-GW group showed the highest body
mass and steatosis degree and although activated HSCs were identiﬁed
after positive immunoreactions for smooth muscle cell alpha actin,
this group showed the lowest ﬁbrosis. This observation is supported
by the suppressive effect that the PPARgamma agonist exerts upon the
ﬁbrogenic potential of HSCs [35,36]. Activated HSCs were also observed
in animals treated with fenoﬁbrate, which can be accounted for by
the recently described greater phosphorylation of p38 and c-Jun N-
terminal kinases by the activation of PPARbeta [37].This study does have some limitations.We aimed to perform a trans-
lational research, and as such, we did not use a PPARbeta/delta agonist
because it is not currently available in clinical practice due to its pro-
carcinogenic effects [38]. As a result, we attempted tomimic the clinical
uses of fenoﬁbrate (PPARalpha agonist), pioglitazone (PPARgamma
agonist) and bezaﬁbrate (pan-PPAR agonist) in the treated mice.
Conclusion
The present ﬁndings highlight the importance of PPARalpha activa-
tion to counteract liver steatosis, insulin resistance, liver inﬂammation,
and overweight/obesity. The WY14643 and bezaﬁbrate treatments
emerged as the most powerful approaches to overcoming the adverse
metabolic and hepatic effects caused by obesity and IR. These observa-
tions conﬁrmed that PPARalpha is the master regulator of the beta-
oxidation target genes and elucidated the inﬂuence of Pan-PPAR
activation on PPARgamma gene expression. Although bezaﬁbrate acti-
vated the three PPAR isoforms, PPARalpha, and PPARbeta/delta levels
seemed to surpass PPARgamma. This observation emphasizes the
pivotal role of PPARalpha and its balance with PPARgamma gene
expression in the regulation of metabolic homeostasis and lipolytic
pathways in the liver.
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